endothelial growth factor agents for retinal diseases and provide an update about their development. ? DESIGN: Literature review. ? METHODS: A comprehensive literature review was performed for scientific articles, clinical trials, and press releases for the development of biosimilars in ophthalmology. ? RESULTS: To date, Razumab (Intas Pharmaceuticals Ltd, Ahmedabad, GJ, India) is the only approved biosimilar for ophthalmic use, but the landscape will rapidly change in the future with multiple biosimilar candidates, which are currently in phase 3 trials, showing promising early results. ? CONCLUSION: Biosimilars hold the potential to reduce the financial burden of the highly efficacious biologic therapy in retinal pathologies. However, the off-label bevacizumab may differentiate the success of biosimilars in different geographic regions. (Am J Ophthalmol 2021;224:36?42. ? 2020 Elsevier Inc. All rights reserved.)
Biosimilars for Retinal Diseases: An Update / Sharma, Ashish; Kumar, Nilesh; Parachuri, Nikulaa; Bandello, Francesco; Kuppermann, Baruch D; Loewenstein, Anat. - In: AMERICAN JOURNAL OF OPHTHALMOLOGY. - ISSN 1879-1891. - 224:(2021), pp. 36-42. [10.1016/j.ajo.2020.11.017]
Biosimilars for Retinal Diseases: An Update
Bandello, Francesco;
2021-01-01
Abstract
endothelial growth factor agents for retinal diseases and provide an update about their development. ? DESIGN: Literature review. ? METHODS: A comprehensive literature review was performed for scientific articles, clinical trials, and press releases for the development of biosimilars in ophthalmology. ? RESULTS: To date, Razumab (Intas Pharmaceuticals Ltd, Ahmedabad, GJ, India) is the only approved biosimilar for ophthalmic use, but the landscape will rapidly change in the future with multiple biosimilar candidates, which are currently in phase 3 trials, showing promising early results. ? CONCLUSION: Biosimilars hold the potential to reduce the financial burden of the highly efficacious biologic therapy in retinal pathologies. However, the off-label bevacizumab may differentiate the success of biosimilars in different geographic regions. (Am J Ophthalmol 2021;224:36?42. ? 2020 Elsevier Inc. All rights reserved.)| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0002939420306516-main.pdf
solo gestori archivio
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Copyright dell'editore
Dimensione
225.65 kB
Formato
Adobe PDF
|
225.65 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
